Eli Lilly to acquire Verve Therapeutics for up to $1.3B

Eli Lilly is acquiring cardiovascular disease drug developer Verve Therapeutics in a deal worth up to $1.3 billion.

Why it matters: Biotech M&A activity is heating up, following two other notable deals earlier this month.